Troy Lister, PhD, is Head of Chemistry at Spero Therapeutics in Cambridge, MA. Dr. Lister previously held roles as Team Leader of Infection Chemistry at AstraZeneca and Investigator III in Global Discovery Chemistry at the Novartis Institute for BioMedical Research. He has lead numerous discovery programs searching for novel agents targeting bacterial and viral pathogens including multidrug resistant Gram negative and Gram positive bacteria, hepatitis C virus, human rhinovirus, respiratory syncytial virus, ebola virus and human enterovirus. Dr. Lister has led programs from the earliest stages of target selection and high throughput screening, through lead identification and optimization, to candidate selection and IND enablement. He is an author of 15 peer review publications, has extensive experience in natural product chemistry and is a member of the American Chemical Society.
Dr. Lister received his B.Tech, B.S. and PhD degrees from Flinders University in Adelaide, Australia, and completed a post-doctoral fellowship at The Scripps Research Institute in La Jolla, California with Professoer K.C. Nicolaou.